These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7849201)

  • 1. [Quality assurance in nursing: nursing standard. Nausea, gagging and vomiting during emetogenic cytostatic therapies. Report of research into the development and introduction of nursing standards].
    Schiener P; Hertig A; Quevedo C; Schlegel S; Studer M
    Pflege; 1994 Dec; 7(4):261-71. PubMed ID: 7849201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and cost effectiveness of new antiemetic guidelines.
    Engstrom C; Hernandez I; Haywood J; Lilenbaum R
    Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Grunberg SM
    J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
    Jordan K; Voigt W; Schmoll HJ
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
    Smith AR; Repka TL; Weigel BJ
    Pediatr Blood Cancer; 2005 Nov; 45(6):857-60. PubMed ID: 15849684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
    Anastasia PJ
    Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action research and the process of continual quality improvement in a cancer center.
    Patton MD
    Oncol Nurs Forum; 1993 Jun; 20(5):751-5. PubMed ID: 8337169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WISECARE+: Results of a European study of a nursing intervention for the management of chemotherapy-related symptoms.
    Kearney N; Miller M; Maguire R; Dolan S; MacDonald R; McLeod J; Maher L; Sinclair L; Norrie J; Wengström Y
    Eur J Oncol Nurs; 2008 Dec; 12(5):443-8. PubMed ID: 18842457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.